Second transplant for acute and chronic leukemia relapsing after first HLA-identical sibling transplant.
about
Juvenile myelomonocytic leukemia: molecular pathogenesis informs current approaches to therapy and hematopoietic cell transplantationCurrent status of hematopoietic stem cell transplant in chronic myeloid leukemiaCosts of second allogeneic hematopoietic cell transplantation.Azacitidine and donor lymphocyte infusions as first salvage therapy for relapse of AML or MDS after allogeneic stem cell transplantation.Salvage therapy with ARA-C and gemtuzumab ozogamicin in AML patients relapsing after stem cell transplantation.Low-dose azacitidine after allogeneic stem cell transplantation for acute leukemiaNCI First International Workshop on the Biology, Prevention, and Treatment of Relapse after Allogeneic Hematopoietic Stem Cell Transplantation: report from the Committee on the Epidemiology and Natural History of Relapse following Allogeneic Cell TrNCI First International Workshop on the Biology, Prevention, and Treatment of Relapse after Allogeneic Hematopoietic Stem Cell Transplantation: Report from the Committee on Treatment of Relapse after Allogeneic Hematopoietic Stem Cell TransplantatioLong-term survival and late effects among one-year survivors of second allogeneic hematopoietic cell transplantation for relapsed acute leukemia and myelodysplastic syndromes.Survival of patients with acute myeloid leukemia relapsing after allogeneic hematopoietic cell transplantation: a center for international blood and marrow transplant research study.Azacitidine for treatment of imminent relapse in MDS or AML patients after allogeneic HSCT: results of the RELAZA trial.PD-1(hi)TIM-3(+) T cells associate with and predict leukemia relapse in AML patients post allogeneic stem cell transplantation.The role of second transplants for leukemia.Phase I study of the safety and pharmacokinetics of plerixafor in children undergoing a second allogeneic hematopoietic stem cell transplantation for relapsed or refractory leukemia.Cellular therapy following allogeneic stem-cell transplantation.Clinical outcomes of AML patients relapsing after matched-related donor and umbilical cord blood transplantation.Same sibling marrow following cord allogeneic transplantation as therapy for second relapse acute promyelocytic leukemia in a pediatric patient.Relapse after allogeneic hematopoietic cell therapy.Viewpoint: What is the role of allogeneic haematopoietic cell transplantation in the era of reduced-intensity conditioning--is there still an upper age limit? A focus on myeloid neoplasia.Treatment options for the management of acute leukaemia relapsing following an allogeneic transplant.Risk factors for lymphoproliferative disorders after allogeneic hematopoietic cell transplantation.Subsequent donation requests among 2472 unrelated hematopoietic progenitor cell donors are associated with bone marrow harvest.Second hematopoietic stem cell transplantation in myeloid malignanciesRelapse after allogeneic stem cell transplantationClinical options after failure of allogeneic hematopoietic stem cell transplantation in patients with hematologic malignancies.Complications of allogeneic hematopoietic stem cell transplantation.Cell-based strategies to manage leukemia relapse: efficacy and feasibility of immunotherapy approaches.Conditioning regimens in acute myeloid leukemia.New strategies of DLI in the management of relapse of hematological malignancies after allogeneic hematopoietic SCT.Major Histocompatibility Mismatch and Donor Choice for Second Allogeneic Bone Marrow Transplantation.Outcome after failure of allogeneic hematopoietic stem cell transplantation in children with acute leukemia: a study by the société Francophone de greffe de moelle et de thérapie cellulaire (SFGM-TC).Comparable post-relapse outcomes between haploidentical and matched related donor allogeneic stem cell transplantation.Role of Second Transplantation for Children With Acute Myeloid Leukemia Following Posttransplantation Relapse.Haploidentical hematopoietic cell transplantation using in vitro T cell depleted grafts as salvage therapy in patients with disease relapse after prior allogeneic transplantation.Second reduced intensity conditioning allogeneic transplant as a rescue strategy for acute leukaemia patients who relapse after an initial RIC allogeneic transplantation: analysis of risk factors and treatment outcomes.Long-term outcome and prognostic factors of second allogeneic hematopoietic stem cell transplant for acute leukemia in patients with a median follow-up of ⩾10 years.Second allogeneic transplantation for relapse of malignant disease: retrospective analysis of outcome and predictive factors by the EBMT.Second Allogeneic Stem Cell Transplantation for Acute Leukemia Using a Chemotherapy-Only Cytoreduction with Clofarabine, Melphalan, and Thiotepa.Efficacy of a 3-day, low-dose treatment with 5-azacytidine followed by donor lymphocyte infusions in older patients with acute myeloid leukemia or chronic myelomonocytic leukemia relapsed after allografting.Monitoring of acute myeloid leukemia patients after allogeneic stem cell transplantation employing semi-automated CD34+ donor cell chimerism analysis.
P2860
Q26851000-42B85508-666E-4B17-8226-372E25545411Q27010475-41CC04A4-3D92-4E81-AFB7-41DC7C21FAFDQ30540989-57F60525-2832-489E-92F2-572C707B6335Q33405278-64156CC4-A4CD-43BC-92B8-4A3C62703BC9Q33418153-4D774535-C388-4316-805E-A891016DF9E3Q33861150-FA4832F6-CF13-409E-98C8-60036613C8DEQ34044024-713219C0-7BF6-4FAE-A914-3978E5C5206AQ34202277-5E4AFE46-31E8-44AB-B61D-266C248D2F5AQ34749088-1EFA4284-4204-4B40-8782-453BCB009453Q35085209-6623457C-9ACA-4EDB-AD79-15CEB57A0505Q35835657-39B3DD01-9B4C-45DF-8A14-4C6474166A83Q35921900-2712403D-11BE-4B17-B6EC-460F09478475Q36204850-204E4B10-0333-488C-881C-03AFB8390D7CQ36243756-776AA414-12BE-4CEE-8371-51733C05D367Q36612643-00C28585-3F87-4242-A2F8-36FD29D06A52Q36623397-22DF2A64-6102-4562-9AA8-C1C42CE688A0Q36729327-34FC5CA3-CD53-4224-9FCE-7AB174021DDEQ36799799-9015866C-92E4-469E-B747-A6115B98B89DQ36824553-FD6596CD-9416-4403-A0B3-F4DB689BD9F3Q36977560-C012CA1F-496B-4BE7-8A6D-536426EDBCC8Q37201899-4A9B8F7C-4205-42E1-813A-A7BD0DD43012Q37377933-184CB1E1-B331-41F7-B7F6-48BFDCC3C792Q37401234-49F70B8D-1FA2-4575-8039-1EFB743E29C7Q37810125-5E7795E2-9767-4FDE-AA74-325EC36DA919Q37905034-6473B541-4A41-4A16-9D34-4FA5B484A606Q38217938-3D5C6F0E-F73D-4DB7-9326-E0FF6A69D9D6Q38219579-B49C0C00-CE92-427E-9062-5E21396C5936Q38229633-1605CD9B-753E-4106-8B88-251E19819DCEQ38643400-6E26DEFF-5603-4E5B-8A3E-300112E8F54DQ38654516-F0DF5906-AE39-4797-AC58-8935F6766152Q39005635-FAB3A50E-AD7B-4815-98A2-597B4AB2F8DDQ39232824-5935029B-DE75-45ED-BB39-7C4A41B14BD5Q40208818-BB0FBFE0-C715-4D2C-9D8C-FA700E394BD4Q40313702-9D2D75D9-841D-42B0-84F8-76BCDF3855C8Q40466623-1C55F15E-14FD-49E6-A04F-538A34D33CFDQ40519376-002A6E3F-2D68-4903-BBAF-3905C3CD378EQ40542266-9AEB2F54-5FB0-422E-95FC-00C541633995Q40752008-4D9E7980-E042-4070-B58D-F2EBBC9A510CQ43283507-79315A40-274E-4318-B171-D0B1EA13C101Q43879358-F752E349-FCC5-44B7-80EF-F74B0D03AD25
P2860
Second transplant for acute and chronic leukemia relapsing after first HLA-identical sibling transplant.
description
2004 nî lūn-bûn
@nan
2004年の論文
@ja
2004年学术文章
@wuu
2004年学术文章
@zh-cn
2004年学术文章
@zh-hans
2004年学术文章
@zh-my
2004年学术文章
@zh-sg
2004年學術文章
@yue
2004年學術文章
@zh
2004年學術文章
@zh-hant
name
Second transplant for acute an ...... -identical sibling transplant.
@en
Second transplant for acute an ...... -identical sibling transplant.
@nl
type
label
Second transplant for acute an ...... -identical sibling transplant.
@en
Second transplant for acute an ...... -identical sibling transplant.
@nl
prefLabel
Second transplant for acute an ...... -identical sibling transplant.
@en
Second transplant for acute an ...... -identical sibling transplant.
@nl
P2093
P2860
P356
P1476
Second transplant for acute an ...... -identical sibling transplant.
@en
P2093
Bredeson CN
Camitta BM
Champlin RE
Horowitz MM
P2860
P2888
P304
P356
10.1038/SJ.BMT.1704645
P407
P577
2004-10-01T00:00:00Z